Cisplatin-Based Combination Chemotherapy for Advanced Hepatocellular Carcinoma: A Single Center Experience before the Sorafenib Era
Open Access
- 1 January 2010
- journal article
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 42 (4) , 203-209
Abstract
Systemic chemotherapy is the only option for patients with unresectable/metastatic hepatocellular carcinoma (HCC) who are not candidates for local/regional treatment. However, the response to such treatment and survival are poor, especially in hepatitis B virus (HBV) endemic areas. The aim of this study was to determine the efficacy of cisplatin-based combination chemotherapy and identify a subgroup of advanced HCC patients with favorable responses. The medical records of all consecutive patients with unresectable/metastatic HCC who received cisplatin-based combination chemotherapy between January 2003 and October 2009 were reviewed. Time to progression (TTP) and overall survival (OS) were determined using Kaplan-Meier analysis. Univariate and multivariate analyses were performed to identify prognostic factors for TTP and OS. Data for 46 patients were analyzed. First-line chemotherapies consisted of cisplatin-based combination treatment with doxorubicin, fluoropyrimidines and gemcitabine. The response rate for all patients was 4.3%. The median TTP and OS were 1.8 (95%confidence interval [CI], 1.1 to 2.5) and 7.2 (95% CI, 3.0 to 11.5) months, respectively. Eastern Cooperative Oncology Group (ECOG) performance status (PS), Child classification, Cancer of the Liver Italian Program (CLIP) score and portal vein thrombosis (PVT) were identified by univariate analyses as prognostic factors for TTP and OS. ECOG PS (hazard ratio [HR], 4.51; 95% CI, 1.61 to 12.6; p=0.004) and PVT (HR, 2.12; 95% CI, 1.10 to 4.11; p=0.026) were independent prognostic factors for TTP. Cisplatin-based combination chemotherapy in patients with advanced HCC has a low response rate and short TTP regardless of the chemotherapy regimen used. Patients with a good ECOG PS and without PVT can be considered candidates for cisplatin-based combination chemotherapy.Keywords
This publication has 24 references indexed in Scilit:
- Hepatocellular carcinoma with main portal vein tumor thrombusCancer, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular CarcinomaJNCI: Journal of the National Cancer Institute, 2005
- A phase II trial of continuous infusion of 5‐fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinomaCancer, 2005
- Systemic therapy for advanced hepatocellular carcinoma: a reviewEuropean Journal of Cancer, 2004
- Simple Clinical Prognostic Model for Hepatocellular Carcinoma in Developing Countries and Its ValidationJournal of Clinical Oncology, 2003
- Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon‐alpha, doxorubicin and 5‐fluorouracil chemotherapyCancer, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patientsHepatology, 1998
- A Phase 2 Study of Cisplatin in Patients with Hepatocellular CarcinomaOncology, 1993